This review explores our current understanding of the risks of (variant) Creutzfeldt-Jakob disease transmission via dental practice, and whether they merit the rigorous enforcement of improved standards of instrument cleaning and decontamination. The recognition of prions as novel infectious agents in humans has caused significant concern among the public and medical professionals alike. Creutzfeldt-Jakob disease (CJD) in humans has been shown to be transmissible via several routes, including transplantation, contaminated medical products, and via neurosurgery. While the likelihood of transmission via dentistry is undoubtedly very low, this may be amplified considerably by unknown risk factors, such as disease prevalence (particularly in the UK), altered tissue distribution of vCJD, and the failure of decontamination processes to address the inactivation of prions adequately. Since current diagnostic techniques are unable to detect PrPSc in human dental tissues, there is limited evidence for the presence of infectivity. Given these uncertainties, the control of risk by reinforced and improved decontamination practices seems the most appropriate response.
Get full access to this article
View all access options for this article.
References
1.
ACDP/SEAC Guidelines: Advisory Committee on Dangerous Pathogens and the Spongiform Encephalopathy Advisory Committee -2003-. Transmissible spongiform encephalopathy agents: safe working and the prevention of infection. http://www.advisorybodies.doh.gov.uk/acdp/tseguidance/ -accessed 3/3/08-.
2.
Arakawa K, Nagara H, Itoyama Y, Dohura K, Tomokane N, Tateishi J, et al. -1991-. Clustering of three cases of Creutzfeldt-Jakob disease near Fukuoka City, Japan. Acta Neurol Scand84:445–447.
3.
Baier M, Schwarz A, Mielke M -2004-. Activity of an alkaline ’cleaner’ in the inactivation of the scrapie agent. J Hosp Infect57:80–84.
4.
Bartz JC, Kincaid AE, Bessen RA -2003-. Rapid prion neuroinvasion following tongue infection. J Virol77:583–591.
5.
Bartz JC, Aiken JM, Bessen RA -2004-. Delay in onset of prion disease for the HY strain of transmissible mink encephalopathy as a result of prior peripheral inoculation with the replication-deficient DY strain. J Gen Virol85-Pt 1-:265–273.
6.
Bartz JC, DeJoia C, Tucker T, Kincaid AE, Bessen RA -2005-. Extraneural prion neuroinvasion without lymphoreticular system infection. J Virol79:11858–11863.
7.
Baxter HC, Campbell GA, Whittaker AG, Jones AC, Aitken A, Simpson AH, et al. -2005-. Elimination of transmissible spongiform encephalopathy infectivity and decontamination of surgical instruments by using radio-frequency gas-plasma treatment. J Gen Virol86-Pt 8-:2393–2399.
Bernoulli C, Siegfried J, Baumgartner G, Regli F, Rabinowicz T, Gajdusek DC, et al. -1977-. Danger of accidental person-to-person transmission of Creutzfeldt-Jakob disease by surgery. Lancet1:478–479.
10.
Bishop MT, Hart P, Aitchison L, Baybutt HN, Plinston C, Thomson V, et al. -2006-. Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurol5:393–398.
11.
Blanquet-Grossard F, Sazdovitch V, Jean A, Deslys JP, Dormont D, Hauw JJ, et al. -2000-. Prion protein is not detectable in dental pulp from patients with Creutzfeldt-Jakob disease [letter]. J Dent Res79:700.
12.
Bourvis N, Boelle PY, Cesbron JY, Valleron AJ -2007-. Risk assessment of transmission of sporadic Creutzfeldt-Jakob disease in endodontic practice in absence of adequate prion inactivation. PLoS ONE2-12-:e1330.
13.
Brown P, Preece M, Brandel JP, Sato T, McShane L, Zerr I, et al. -2000-. Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology55:1075–1081.
14.
Brown SL -1997-. Atmospheric and potable water exposures to methyl tert-butyl ether -MTBE-. Regul Toxicol Pharmacol25:256–276.
15.
Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Suttie A, et al. -1997-. Transmissions to mice indicate that ’new variant’ CJD is caused by the BSE agent. Nature389:498–501.
16.
Carp RI -1982-. Transmission of scrapie by oral route: effect of gingival scarification. Lancet1:170–171.
17.
Casalone C, Corona C, Crescio MI, Martucci F, Mazza M, Ru G, et al. -2005-. Pathological prion protein in the tongues of sheep infected with naturally occurring scrapie. J Virol79:5847–5849.
Clarke P, Ghani AC -2005-. Projections of the future course of the primary vCJD epidemic in the UK: inclusion of subclinical infection and the possibility of wider genetic susceptibility. J R Soc Interface2:19–31.
23.
Collinge J, Harding AE, Owen F, Poulter M, Lofthouse R, Boughey AM, et al. -1989-. Diagnosis of Gerstmann-Straussler syndrome in familial dementia with prion protein gene analysis. Lancet2:15–17.
24.
Collinge J, Owen F, Poulter M, Leach M, Crow TJ, Rossor MN, et al. -1990-. Prion dementia without characteristic pathology. Lancet336:7–9.
25.
Collinge J, Whitfield J, McKintosh E, Beck J, Mead S, Thomas DJ, et al. -2006-. Kuru in the 21st century—an acquired human prion disease with very long incubation periods. Lancet367:2068–2074.
26.
Collins S, Law MG, Fletcher A, Boyd A, Kaldor J, Masters CL -1999-. Surgical treatment and risk of sporadic Creutzfeldt-Jakob disease: a case-control study. Lancet353:693–697.
27.
Collins S, McLean CA, Masters CL -2001-. Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, and kuru: a review of these less common human transmissible spongiform encephalopathies. J Clin Neurosci8:387–397.
28.
Cousens SN, Zeidler M, Esmonde TF, De Silva R, Wilesmith JW, Smith PG, et al. -1997-. Sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of epidemiological surveillance data for 1970–96. BMJ315:389–395.
29.
DeJoia C, Moreaux B, O’Connell K, Bessen RA -2006-. Prion infection of oral and nasal mucosa. J Virol80:4546–4556.
30.
Duffy P, Wolf J, Collins G, DeVoe AG, Streeten B, Cowen D -1974-. Possible person-to-person transmission of Creutzfeldt-Jakob disease [letter]. N Engl J Med290:692–693.
31.
Eklund CM, Kennedy RC, Hadlow WJ -1967-. Pathogenesis of scrapie virus infection in the mouse. J Infect Dis117:15–22.
Fichet G, Comoy E, Duval C, Antloga K, Dehen C, Charbonnier A, et al. -2004-. Novel methods for disinfection of prion-contaminated medical devices. Lancet364:521–526.
34.
Fichet G, Antloga K, Comoy E, Deslys JP, McDonnell G -2007a-. Prion inactivation using a new gaseous hydrogen peroxide sterilisation process. J Hosp Infect67:278–286.
35.
Fichet G, Comoy E, Dehen C, Challier L, Antloga K, Deslys JP, et al. -2007b-. Investigations of a prion infectivity assay to evaluate methods of decontamination. J Microbiol Methods70:511–518.
36.
Gajdusek DC, Gibbs CJ Jr -1971-. Transmission of two subacute spongiform encephalopathies of man -Kuru and Creutzfeldt-Jakob disease- to new world monkeys. Nature230:588–591.
37.
Gajdusek DC, Gibbs CJ Jr, Asher DM, Brown P, Diwan A, Hoffman P, et al. -1977-. Precautions in medical care of, and in handling materials from, patients with transmissible virus dementia -Creutzfeldt-Jakob disease-. N Engl J Med297:1253–1258.
Gill DS, Tredwin CJ, Gill SK, Ironside JW -2001-. The transmissible spongiform encephalopathies -prion diseases-: a review for dental surgeons. Internat Dent J51:439–446.
40.
Groschup M, Beekes M, McBride P, Hardt M, Hainfellner J, Budka H -1999-. Deposition of disease associated prion protein involves the peripheral nervous system in experimental scrapie. Acta Neuropathol98:453–457.
41.
Head MW, Ritchie D, McLoughlin V, Ironside JW -2003-. Investigation of PrPres in dental tissues in variant CJD. Br Dent J195:339–443.
42.
Head MW, Ritchie D, Smith N, McLoughlin V, Nailon W, Samad S, et al. -2004-. Peripheral tissue involvement in sporadic, iatrogenic, and variant Creutzfeldt-Jakob disease: an immunohistochemical, quantitative, and biochemical study. Am J Pathol164:143–153.
Herzog C, Salès N, Etchegaray N, Charbonnier A, Freire S, Dormont D, et al. -2004-. Tissue distribution of bovine spongiform encephalopathy agent in primates after intravenous or oral infection. Lancet363:422–428.
45.
Herzog C, Riviere J, Lescoutra-Etchegaray N, Charbonnier A, Leblanc V, Sales N, et al. -2005-. PrPTSE distribution in a primate model of variant, sporadic, and iatrogenic Creutzfeldt-Jakob disease. J Virol79:14339–14345.
46.
Hewitt PE, Llewelyn CA, Mackenzie J, Will RG -2006-. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang91:221–230.
47.
Hill AF, Desbruslais M, Joiner S, Sidle KC, Gowland I, Collinge J, et al. -1997-. The same prion strain causes vCJD and BSE. Nature389:448–450, 526.
48.
Hill AF, Butterworth RJ, Joiner S, Jackson G, Rossor MN, Thomas DJ, et al. -1999-. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet353:183–189.
49.
Hilton DA, Ghani AC, Conyers L, Edwards P, McCardle L, Ritchie D, et al. -2004-. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol203:733–739.
50.
Hornshaw MP, McDermott JR, Candy JM -1995-. Copper binding to the N-terminal tandem repeat regions of mammalian and avian prion protein. Biochem Biophys Res Commun207:621–629.
51.
Ingrosso L, Pisani F, Pocchiari M -1999-. Transmission of the 263K scrapie strain by the dental route. J Gen Virol80-Pt 11-:3043–3047.
52.
Irish Department of Health -2007-. Advice for dentists on re-use of endodontic instruments and variant Creutzfeldt-Jakob Disease -vCJD-. http://www.dhsspsni.gov.uk/cjd_endo_april_2007.pdf -accessed 3/3/08-.
53.
Ironside JW, Sutherland K, Bell JE, McCardle L, Barrie C, Estebeiro K, et al. -1996-. A new variant of Creutzfeldt-Jakob disease: neuro -pathological and clinical features. Cold Spring Harb Symp Quant Biol61:523–530.
54.
Ironside JW, Head MW, Bell JE, McCardle L, Will RG -2000-. Laboratory diagnosis of variant Creutzfeldt-Jakob disease. Histopathology37:1–9.
55.
Ironside JW, McCardle L, Horsburgh A, Lim Z, Head MW -2002-. Pathological diagnosis of variant Creutzfeldt-Jakob disease. APMIS110:79–87.
56.
Ironside JW, Bishop MT, Connolly K, Hegazy D, Lowrie S, Le Grice M, et al. -2006-. Variant Creutzfeldt-Jakob disease: prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study. BMJ332:1186–1188; erratum in BMJ 333:416, 2006.
57.
Jackson GS, McKintosh E, Flechsig E, Prodromidou K, Hirsch P, Linehan J, et al. -2005-. An enzyme-detergent method for effective prion decontamination of surgical steel. J Gen Virol86:869–878.
58.
Joiner S, Linehan JM, Brandner S, Wadsworth JD, Collinge J -2005-. High levels of disease related prion protein in the ileum in variant Creutzfeldt-Jakob disease. Gut54:1506–1508.
59.
Kincaid AE, Bartz JC -2007-. The nasal cavity is a route for prion infection in hamsters. J Virol81:4482–4491.
60.
Kordek R -2000-. The diagnosis of human prion diseases. Folia Neuropathol38-4-:151–160.
61.
Kuwahara C, Takeuchi AM, Nishimura T, Haraguchi K, Kubosaki A, Matsumoto Y, et al. -1999-. Prions prevent neuronal cell-line death. Nature400:225–226.
62.
Lantos PL, McGill IS, Janota I, Doey LJ, Collinge J, Bruce MT, et al. -1992-. Prion protein immunocytochemistry helps to establish the true incidence of prion diseases. Neurosci Lett147:67–71.
63.
Lasmezas CI -2003-. Putative functions of PrP-C-. Br Med Bull66:61–70.
64.
Lee CC, Kuo LT, Wang CH, Scaravilli F, An SF -2005-. Accumulation of prion protein in the peripheral nervous system in human prion diseases. J Neuropathol Exp Neurol64:716–721.
65.
Lemmer K, Mielke M, Pauli G, Beekes M -2004-. Decontamination of surgical instruments from prion proteins: in vitro studies on the detachment, destabilization and degradation of PrPSc bound to steel surfaces. J Gen Virol85-Pt 12-:3805–3816.
66.
Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, Mackenzie J, et al. -2004-. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet363:417–421.
67.
Masters CL, Harris JO, Gajdusek DC, Gibbs CJ Jr, Bernoulli C, Asher DM -1979-. Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann Neurol5:177–188.
68.
Mathiason CK, Powers JG, Dahmes SJ, Osborn DA, Miller KV, Warren RJ, et al. -2006-. Infectious prions in the saliva and blood of deer with chronic wasting disease. Science314:133–136.
69.
McLeod AH, Murdoch H, Dickinson J, Dennis MJ, Hall GA, Buswell CM, et al. -2004-. Proteolytic inactivation of the bovine spongiform encephalopathy agent. Biochem Biophys Res Commun317:1165–1170.
70.
Mead S, Joiner S, Desbruslais M, Beck JA, O’Donoghue M, Lantos P, et al. -2007-. Creutzfeldt-Jakob disease, prion protein gene codon 129VV, and a novel PrPSc type in a young British woman. Arch Neurol64:1780–1784.
71.
Moudjou M, Frobert Y, Grassi J, La Bonnardière C -2001-. Cellular prion protein status in sheep: tissue-specific biochemical signatures. J Gen Virol82-Pt 8-:2017–2024.
72.
Mouillet-Richard S, Ermonval M, Chebassier C, Laplanche JL, Lehmann S, Launay JM, et al. -2000-. Signal transduction through prion protein. Science289:1925–1928.
73.
Mulcahy ER, Bartz JC, Kincaid AE, Bessen RA -2004-. Prion infection of skeletal muscle cells and papillae in the tongue. J Virol78:6792–6798.
74.
Murdoch H, Walker J, Sutton J, Raven N -2007-. Transmission of vCJD by surgery; perception, risks and research. J Instit Decon Sci11:36–39.
75.
Pattison IH, Millson GC -1962-. Distribution of the scrapie agent in the tissues of experimentally inoculated goats. J Comp Pathol72:233–244.
76.
Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW -2004-. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet364:527–529.
77.
Peretz D, Supattapone S, Giles K, Vergara J, Freyman Y, Lessard P, et al. -2006-. Inactivation of prions by acidic sodium dodecyl sulfate. J Virol80:322–331.
78.
Porter SR -2003-. Prion disease: possible implications for oral health care. J Am Dent Assoc134:1486–1491.
79.
Rosenberg U -2005-. Effective cleaning processes and efficacy against prions. Zentr Steril13:258–270.
80.
Sakaguchi S, Katamine S, Yamanouchi K, Kishikawa M, Moriuchi R, Yasukawa N, et al. -1993-. Kinetics of infectivity are dissociated from PrP accumulation in salivary glands of Creutzfeldt-Jakob disease agent-inoculated mice. J Gen Virol74-Pt 10-:2117–2123.
81.
Scully C, Smith AJ, Bagg J -2003-. Prions and the human transmissible spongiform encephalopathies. Dent Clin North Am47:493–516.
82.
Sehulster LM -2004-. Prion inactivation and medical instrument reprocessing: challenges facing healthcare facilities. Infect Control Hosp Epidemiol25:276–279.
83.
Smith A, Letters S, Lange A, Perrett D, McHugh S, Bagg J -2005-. Residual protein levels on reprocessed dental instruments. J Hosp Infect61:237–241.
84.
Smith AJ, Bagg J, Ironside JW, Will RG, Scully C -2003-. Prions and the oral cavity. J Dent Res82:769–775.
85.
Sutton JM, Dickinson J, Walker JT, Raven ND -2006-. Methods to minimize the risks of Creutzfeldt-Jakob disease transmission by surgical procedures: where to set the standard? Clin Infect Dis43:757–764.
86.
Taylor D -1996-. Exposure to, and inactivation of the unconventional agents that cause transmissible degenerative encephalopathies. In: Prion diseases. Baker H, Ridley R, editors. Totowa, NJ: Humana Press, pp. 105–118.
87.
Thomzig A, Kratzel C, Lenz G, Kruger D, Beekes M -2003-. Widespread PrPsc accumulation in muscles of hamsters orally infected with scrapie. EMBO Rep4:530–533.
88.
van Keulen LJ, Schreuder BE, Vromans ME, Langeveld JP, Smits MA -2000-. Pathogenesis of natural scrapie in sheep. Arch Virol Suppl16:57–71.
89.
Vascellari M, Nonno R, Mutinelli F, Bigolaro M, Di Bari MA, Melchiotti E, et al. -2007-. PrPSc in salivary glands of scrapie-affected sheep. J Virol81:4872–4876.
90.
Wadsworth JD, Joiner S, Hill AF, Campbell TA, Desbruslais M, Luthert PJ, et al. -2001-. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet358:171–180.
91.
Wadsworth JD, Asante EA, Desbruslais M, Linehan JM, Joiner S, Gowland I, et al. -2004-. Human prion protein with valine 129 prevents expression of variant CJD phenotype. Science306:1793–1796.
92.
Walker JT, Dickinson J, Sutton JM, Raven ND, Marsh PD -2007-. Cleanability of dental instruments—implications of residual protein and risks from Creutzfeldt-Jakob disease. Br Dent J203:395–401.
93.
Wells GA, Hawkins S, Green RB, Austin AR, Dexter I, Spencer YJ, et al. -1998-. Preliminary observations on the pathogenesis of experimental bovine spongiform encephalopathy -BSE-: an update. Vet Rec142:103–106.
Wilesmith JW, Wells GA, Cranwell MP, Ryan JB -1988-. Bovine spongiform encephalopathy: epidemiological studies. Vet Rec123:638–644.
98.
Will RG -1999-. The transmission of prions to humans. Acta Paediatr Suppl433:28–32.
99.
Will RG -2003-. Acquired prion disease: iatrogenic CJD, variant CJD, kuru. Br Med Bull66:255–265.
100.
Will RG, Matthews W -1982-. Evidence for case-to-case transmission of Creutzfeldt-Jakob disease. J Neurol Neurosci Psychiatry45:235–238.
101.
Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, et al. -1996-. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet347:921–925.
102.
Williams ES, Young S -1980-. Chronic wasting disease of captive mule deer: a spongiform encephalopathy. J Wildl Dis16:89–98.
103.
Wroe SJ, Pal S, Siddique D, Hyare H, Macfarlane R, Joiner S, et al. -2006-. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet368:2061–2067.
104.
Yan ZX, Stitz L, Heeg P, Pfaff E, Roth K -2004-. Infectivity of prion protein bound to stainless steel wires: a model for testing decontamination procedures for transmissible spongiform encephalopathies. Infect Control Hosp Epidemiol25:280–283.
105.
Zobeley E, Flechsig E, Cozzio A, Enari M, Weissmann C -1999-. Infectivity of scrapie prions bound to a stainless steel surface. Mol Med5:240–243.
